{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:26:35Z","timestamp":1794137195087,"version":"4.8.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ODYSSEY OUTCOMES","award":["NCT01663402"],"award-info":[{"award-number":["NCT01663402"]}]},{"name":"Sanofi and Regeneron Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab reduced lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and cardiovascular events compared with placebo. This post hoc analysis determined whether baseline levels and alirocumab-induced changes in lipoprotein(a) and LDL-C [corrected for lipoprotein(a) cholesterol] independently predicted total cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Cardiovascular events included cardiovascular death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina or heart failure, ischaemia-driven coronary revascularization, peripheral artery disease events, and venous thromboembolism. Proportional hazards models estimated relationships between baseline lipoprotein(a) and total cardiovascular events in the placebo group, effects of alirocumab treatment on total cardiovascular events by baseline lipoprotein(a), and relationships between lipoprotein(a) reduction with alirocumab and subsequent risk of total cardiovascular events. Baseline lipoprotein(a) predicted total cardiovascular events with placebo, while higher baseline lipoprotein(a) levels were associated with greater reduction in total cardiovascular events with alirocumab (hazard ratio P \u00a0trend = 0.045). Alirocumab-induced reductions in lipoprotein(a) (median \u22125.0 [\u221213.6, 0] mg\/dL) and corrected LDL-C (median \u221251.3 [\u221267.1, \u221234.0] mg\/dL) independently predicted lower risk of total cardiovascular events. Each 5-mg\/dL reduction in lipoprotein(a) predicted a 2.5% relative reduction in cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline lipoprotein(a) predicted the risk of total cardiovascular events and risk reduction by alirocumab. Lipoprotein(a) lowering contributed independently to cardiovascular event reduction, supporting the concept of lipoprotein(a) as a treatment target after ACS.<\/jats:p>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaa649","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T15:13:38Z","timestamp":1595603618000},"page":"4245-4255","source":"Crossref","is-referenced-by-count":213,"title":["Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, State University of New York, Downstate School of Public Health , 450 Clarkson Avenue, MS 43, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera A","family":"Bittner","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , 701 19th Street South - LHRB 310, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Aylward","sequence":"additional","affiliation":[{"name":"Department of Cardiology, South Australian Health and Medical Research Institute, Flinders University and Medical Centre , South Australia 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Baccara-Dinet","sequence":"additional","affiliation":[{"name":"Sanofi R&D, Global Development, 371 Rue du Professeur Blayac, 34080 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital Heart and Vascular Center , Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"Estudios Cl\u00ednicos Latinoam\u00e9rica, Instituto Cardiovascular de Rosario, Paraguay 160, Rosario, Santa Fe, Rosario 2000, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0442-6175","authenticated-orcid":false,"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[{"name":"Preventive Cardiology Unit, Department of Vascular Medicine, Division of Medicine, University Medical Centre Ljubljana, Zalo\u0161ka cesta 7, SI-1525 Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Vrazov trg 2, SI-1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-2440","authenticated-orcid":false,"given":"Shaun G","family":"Goodman","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , 87 Ave NW, Edmonton, Alberta T6G 2E1, Canada"},{"name":"Division of Cardiology, St. Michael\u2019s Hospital , Room 6-034 Donnelly Wing, Toronto, Ontario M5B 1W8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-7644","authenticated-orcid":false,"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo Universitetssykehus HF Ulleval, and University of Oslo, Problemveien 7, 0315 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Harrington","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research, Department of Medicine, Stanford University , 291 Campus Drive, Li Ka Shing Building, Stanford, CA 94305-5101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3246-8359","authenticated-orcid":false,"given":"J Wouter","family":"Jukema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Netherlands Heart Institute, Utrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology\u2014University of Kansas Medical Center , 3901 Rainbow Blvd, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-6795","authenticated-orcid":false,"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals , 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London , Reynolds Building, St Dunstans Road, London W6 8RP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sinnaeve","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospitals Leuven , Herestraat 49, Leuven 3000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego , 9434 Medical Center Dr, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-5052","authenticated-orcid":false,"given":"Robert","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado Denver , 13001 E 17th Pl, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-6750","authenticated-orcid":false,"given":"Harvey D","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Services, Auckland City Hospital , 5 Park Road, Grafton, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Zahger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev , PO Box 151 Beer Sheva 8410, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M","family":"Zeiher","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Goethe University , Theodor-Stern-Kai 7, Frankfurt am Main 60590, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat, Universit\u00e9 de Paris, FACT (French Alliance for Cardiovascular Trials) , INSERM U1148, 46 Rue Henri Huchard, Paris 75018, France"},{"name":"National Heart and Lung Institute, Imperial College, Royal Brompton Hospital , Sydney St, Chelsea, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine , Box B130, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ODYSSEY OUTCOMES Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"2022102514564550300_ehaa649-B1","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102514564550300_ehaa649-B2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022102514564550300_ehaa649-B3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102514564550300_ehaa649-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514564550300_ehaa649-B5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102514564550300_ehaa649-B6","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of a randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"2022102514564550300_ehaa649-B7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2022102514564550300_ehaa649-B8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"2022102514564550300_ehaa649-B9","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102514564550300_ehaa649-B10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102514564550300_ehaa649-B11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2022102514564550300_ehaa649-B12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10985-019-09462-4","article-title":"Modeling marginal features in studies of recurrent events in the presence of a terminal event","volume":"25","author":"Andersen","year":"2019","journal-title":"Lifetime Data Anal"},{"key":"2022102514564550300_ehaa649-B13","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/sim.4780131709","article-title":"Standardized rates of recurrent outcomes","volume":"13","author":"Stukel","year":"1994","journal-title":"Stat Med"},{"key":"2022102514564550300_ehaa649-B14","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514564550300_ehaa649-B15","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","article-title":"Lipoprotein(a)-cholesterol: a significant component of serum cholesterol","volume":"412","author":"Kinpara","year":"2011","journal-title":"Clin Chim Acta"},{"key":"2022102514564550300_ehaa649-B16","doi-asserted-by":"crossref","first-page":"154221","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/44\/4245\/46626967\/ehaa649.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/44\/4245\/46626967\/ehaa649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:47:55Z","timestamp":1666705675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/44\/4245\/5922803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":16,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020,10,14]]},"published-print":{"date-parts":[[2020,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa649","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,21]]},"published":{"date-parts":[[2020,10,14]]}}}